Fletcher Allen Hospital   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Burlington VT United States (1879)

Organization Overview

First Clinical Trial
2008
NCT00595868
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Fletcher Allen Health Care, Dept. of Psychiatry

Active Ingredients

Drugs in Phase 4 Trials (2)

beractant (survanta) (1 trial)

thienoyridine (1 trial)

Drugs in Phase 2 Trials (3)

bradanicline (1 trial)

buprenorphine (1 trial)

varenicline (chantix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 2)

Coronary Artery Disease (Phase 4)

Opioid-Related Disorders (Phase 2)

Tobacco Use Disorder (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5